The primary efficacy endpoint of clinically-relevant bleeding, defined as BARC types 2, 3 or 5 bleeding, was assessed in the intention-to-treat population between one-month and twelve-months post-PCI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback